Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.43 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.42 |
| ▸ | HINT1 | P49773 | 3/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579548 | 1.00 | POLB (0.49) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL12570242 | 0.90 | POLB (0.51) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL16844109 | 0.90 | POLB (0.51) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL1514931 | 0.90 | POLB (0.51) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL7613803 | 0.90 | POLB (0.51) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL4578872 | 0.90 | POLB (0.51) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL427927 | 0.87 | POLB (0.48) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL887469 | 0.87 | POLB (0.48) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL427928 | 0.87 | POLB (0.48) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL21538191 | 0.86 | POLB (0.48) | POLBP2RY2P2RY4P2RY6FUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0649429-B1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2008-08-27 | — | — | EP | disclosed |
| US-6214551-B1 | CONTACTING TEST SOLUTION CONTAINING NUCLEIC ACID WITH COMPOUND CONTAINING NUCLEOSIDE SEQUENCE WHEREIN NUCLEOSIDES ARE COVALENTLY BOUND THROUGH LINKING GROUP HAVING ADJACENT NITROGEN ATOMS FOR ASSAYING SEQUENCE-SPECIFIC NUCLEIC ACID | ISIS PHARMACEUTICALS, INC. | 2001-04-10 | — | — | US | disclosed |
| US-6025482-A | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5969118-A | NUCLEOSIDES AND OLIGONUCLEOTIDES WITH INCREASED NUCLEASE RESISTANCE AND CELLULAR UPTAKE; FOR DIAGNOSIS AND ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5808023-A | Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5792844-A | MIMIC AND/OR MODULATE THE ACTIVITY OF WILD-TYPE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5777092-A | Heteroatomic oligonucleoside linkages | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5623070-A | Heteroatomic oligonucleoside linkages | ISIS PHARMACEUTICALS, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5618704-A | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling | ISIS PHARMACUETICALS, INC. (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0649429-A4 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES. | ISIS PHARMACEUTICALS INC (US) | 1996-04-10 | — | — | EP | disclosed |
| US-5489677-A | NUCLEASE RESISTANT OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0649429-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5386023-A | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling | ISIS PHARMACEUTICALS (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1994022894-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND PREPARATION THEREOF THROUGH RADICAL COUPLING | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022883-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDES AND THEIR PREPARATION | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022893-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022454-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT OXYGEN AND NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994000467-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | disclosed |